Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.700 AlteredExpression disease BEFREE Using mature miRNA profiling and quantitative real-time PCR (qRT-PCR) in the orbitofrontal cortex (OFC) of SCZ (N = 29; 20 male and 9 female), BD (N = 26; 12 male and 14 female), and unaffected control (N = 25; 21 male and 4 female) subjects, we uncovered that miR-223, an exosome-secreted miRNA that targets glutamate receptors, was increased at the mature miRNA level in the OFC of SCZ and BD patients with positive history of psychosis at the time of death and was inversely associated with deficits in the expression of its targets glutamate ionotropic receptor NMDA-type subunit 2B (GRIN2B) and glutamate ionotropic receptor AMPA-type subunit 2 (GRIA2). 31775160 2020
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.560 Biomarker phenotype BEFREE This study investigated the role of SAP102 in the formation of hyperalgesia in rats with CIBP SAP102 is present in spinal dorsal horn neurons, but not in astrocytes or microglia.NMDAR-NR2B is localized with neurons. 31682872 2020
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.390 AlteredExpression disease BEFREE Using mature miRNA profiling and quantitative real-time PCR (qRT-PCR) in the orbitofrontal cortex (OFC) of SCZ (N = 29; 20 male and 9 female), BD (N = 26; 12 male and 14 female), and unaffected control (N = 25; 21 male and 4 female) subjects, we uncovered that miR-223, an exosome-secreted miRNA that targets glutamate receptors, was increased at the mature miRNA level in the OFC of SCZ and BD patients with positive history of psychosis at the time of death and was inversely associated with deficits in the expression of its targets glutamate ionotropic receptor NMDA-type subunit 2B (GRIN2B) and glutamate ionotropic receptor AMPA-type subunit 2 (GRIA2). 31775160 2020
CUI: C0338656
Disease: Impaired cognition
Impaired cognition
0.190 Biomarker disease BEFREE Pretreatment with GLYX-13 ameliorated isoflurane exposure-induced cognitive impairment and restored NR2B, CaMKII and CREB mRNA and phosphorylated protein levels. 31535661 2020
CUI: C0027796
Disease: Neuralgia
Neuralgia
0.100 AlteredExpression phenotype BEFREE This study aims to determine whether caveolin-1 (Cav-1) participates in the process of diabetic neuropathic pain by directly regulating the expression of toll-like receptor 4 (TLR4) and the subsequent phosphorylation of N-methyl-D-aspartate receptor 2B subunit (NR2B) in the spinal cord. 31318049 2020
CUI: C0030193
Disease: Pain
Pain
0.100 AlteredExpression phenotype BEFREE Ginger extracts and its compound, 6-shogaol, reduced pain symptoms in PDN via its effect on decreasing TRPV1 and NMDAR2B expressions in the spinal cord, with very limited effect on pancreatic islets. 31743763 2020
CUI: C0033975
Disease: Psychotic Disorders
Psychotic Disorders
0.030 AlteredExpression group BEFREE Using mature miRNA profiling and quantitative real-time PCR (qRT-PCR) in the orbitofrontal cortex (OFC) of SCZ (N = 29; 20 male and 9 female), BD (N = 26; 12 male and 14 female), and unaffected control (N = 25; 21 male and 4 female) subjects, we uncovered that miR-223, an exosome-secreted miRNA that targets glutamate receptors, was increased at the mature miRNA level in the OFC of SCZ and BD patients with positive history of psychosis at the time of death and was inversely associated with deficits in the expression of its targets glutamate ionotropic receptor NMDA-type subunit 2B (GRIN2B) and glutamate ionotropic receptor AMPA-type subunit 2 (GRIA2). 31775160 2020
CUI: C0349204
Disease: Nonorganic psychosis
Nonorganic psychosis
0.030 AlteredExpression disease BEFREE Using mature miRNA profiling and quantitative real-time PCR (qRT-PCR) in the orbitofrontal cortex (OFC) of SCZ (N = 29; 20 male and 9 female), BD (N = 26; 12 male and 14 female), and unaffected control (N = 25; 21 male and 4 female) subjects, we uncovered that miR-223, an exosome-secreted miRNA that targets glutamate receptors, was increased at the mature miRNA level in the OFC of SCZ and BD patients with positive history of psychosis at the time of death and was inversely associated with deficits in the expression of its targets glutamate ionotropic receptor NMDA-type subunit 2B (GRIN2B) and glutamate ionotropic receptor AMPA-type subunit 2 (GRIA2). 31775160 2020
CUI: C0751074
Disease: Diabetic Neuralgia
Diabetic Neuralgia
0.030 Biomarker disease BEFREE This study aimed to investigate the mechanism of action of ginger extract and its compound, 6-shogaol, on pancreatic islets as well as on expressions of TRPV-1 and NMDAR2B in the spinal cord of streptozotocin (STZ)-induced mice model of PDN. 31743763 2020
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.700 Biomarker disease BEFREE In a recent weighted burden analysis of exome-sequenced schizophrenia cases and controls, we noted modest statistical evidence for an enrichment of rare, functional variants in FYN, GRIN1, and GRIN2B in schizophrenia cases. 30664045 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.700 PosttranslationalModification disease BEFREE Changes in GRIN2B promoter methylation may represent an environmental influence contributing to glutamatergic dysfunction in psychosis and relate to lower cognitive performance in subjects with first-episode schizophrenia. 30785307 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.560 Biomarker phenotype BEFREE Then, we intrathecally injected MK-801 (an NMDAR inhibitor) and ifenprodil (a selective NR2B subunit antagonist) and observed that the two types of inhibitors not only alleviated masseter hyperalgesia but also significantly inhibited the phosphorylation of JNK in the Vc after restraint stress; this indicates that the effect of NMDAR antagonists may influence the activation of astrocytic JNK. 31798413 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.560 Biomarker phenotype BEFREE Moreover, pretreatment with AMD3100 reduced hyperalgesia and NR2B-containing NMDAR phosphorylation. 30120960 2019
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.400 AlteredExpression disease BEFREE Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus. 31488789 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.400 AlteredExpression disease BEFREE Magnesium and ketamine have a common mechanism of action in the treatment of depression: an increase in GluN2B (NMDAR subunit) expression is related to the administration of both of the agents, as well as inhibition of phosphorylation of eEF2 (eukaryotic elongation factor 2) in cell culture and increase of the expression of BDNF in the hippocampus. 31488789 2019
CUI: C1510586
Disease: Autism Spectrum Disorders
Autism Spectrum Disorders
0.380 Biomarker disease BEFREE Analysis of <i>de novo</i> mutations identified <i>GRIN2B</i>, which encodes the GluN2B subunit of NMDA receptors, as a gene linked to ASDs with high probability. 31548203 2019
CUI: C1510586
Disease: Autism Spectrum Disorders
Autism Spectrum Disorders
0.380 AlteredExpression disease BEFREE Symptomatic mice presenting ASD-like behavior showed decreased levels of GABA pathway proteins such as GAD65/67 and VGAT and altered ratios of the glutamate receptor subunits GluR1/GluR2 in males and NR2A/NR2B in females. 31133774 2019
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia
0.360 AlteredExpression phenotype BEFREE Paclitaxel also upregulated the expression of glutamate receptor subunits GluR1 and NR2B, decreased the expression of K<sup>+</sup>-Cl<sup>-</sup> cotransporter, and induced mechanical allodynia in rats. 30414958 2019
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia
0.360 Biomarker phenotype BEFREE Intrathecal administration of FLRT3 protein to naive rats induced mechanical allodynia and GluN2B phosphorylation in the spinal cord. 31346030 2019
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.180 Biomarker phenotype BEFREE These findings highlight the importance of mental health of females before pregnancy and suggest that CUS before pregnancy reduces p-CREB and p-NR2B in the offspring hippocampus, which could be responsible for behavioral disorders in the adolescent offspring. 31419724 2019
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.180 Biomarker phenotype BEFREE Taken together, our results revealed a specific enhancement of GluN2B-containing NMDARs by 24HC, indicating a novel endogenous pathway to influence a subclass of NMDARs critically involved in cortical plasticity and in numerous neurological and psychiatric disorders. 30594698 2019
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.180 AlteredExpression phenotype BEFREE We also used gap-prepulse inhibition of the acoustic startle reflex (GPIAS) and noise burst prepulse inhibition of acoustic startle, and the auditory brainstem level (electrophysiological recordings of auditory brainstem responses, ABR) and NR2B expression level in the auditory cortex to evaluate whether memantine could reduce salicylate-mediated behavioral disturbances. 31495078 2019
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.140 PosttranslationalModification disease BEFREE <i>N</i>-methyl-D-aspartate receptor (NMDAR) subunit NR2B tyrosine phosphorylation mediated by Src family protein tyrosine kinases is closely associated with dyskinesia. 30350722 2019
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.140 Biomarker disease BEFREE These findings suggest that targeting NR2B/Src complexes can be one potential treatment for dyskinesia in Parkinson's disease. 30130562 2019
CUI: C0683322
Disease: Mental impairment
Mental impairment
0.110 Biomarker disease BEFREE Missense variants of GRIN1, GRIN2A, and GRIN2B cause similar syndromes with varying severity of intellectual impairment, autism, epilepsy, and motor dysfunction. 31299220 2019